Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
NCT02112526
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class
Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
Interventions
DRUG:
Acalabrutinib
Sponsor
Acerta Pharma BV